LEO Pharma presented results from the Phase III PSO-LONG clinical trial comparing the efficacy and safety of twice-weekly Enstilar (calcipotriene and betamethasone dipropionate) foam, versus foam vehicle for… read more.
AbbVie announced new late-breaking IMMerge Phase IIIb open-label study head-to-head data showing superior rates of skin clearance for Skyrizi (risankizumab)to Cosentyx (secukinumab) at week 52 in psoriasis. Particularly,… read more.
Sun Pharmaceutical Industries announced further evidence of the long-term use and cost-effectiveness of Ilumya (tildrakizumab-asmn) in moderate-to-severe plaque psoriasis. Long-term analyses of the phase III reSURFACE 1 and… read more.
Sun Pharmaceutical Industries announced further evidence of the long-term use and cost-effectiveness of Ilumya (tildrakizumab-asmn) in moderate-to-severe plaque psoriasis. Long-term analyses of the phase III reSURFACE 1 and… read more.
Pfizer Inc. announced that JAMA Dermatology has published complete results from the second Phase III monotherapy pivotal study (JADE MONO-2) of PF 04965842 (abrocitinib), an investigational oral once-daily… read more.
The pivotal Phase III clinical trial results announced show Dupixent (dupilumab) combined with standard-of-care topical corticosteroids (TCS) from Sanofi + Regeneron ,in children aged 6-11 years with uncontrolled… read more.
Novartis, announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cosentyx (secukinumab) for the treatment… read more.
University of Queensland scientists have identified a way to help dermatologists determine a patient’s risk of developing melanoma.
Not all fats are equal in how they affect our skin, according to a new study in the Journal of Investigative Dermatology
Adding antibiotic treatment to standard drainage of simple skin abscesses appears to improve healing, researchers reported on June 29, 2017 in the NEJM/New England Journal of Medicine.
by Bruce Sylvester: Psoriasis appears to be associated with type 2 diabetes, body mass index and obesity, researchers from a twin study reported on April 27, 2016 in… read more.
by Bruce Sylvester: Treatment with nicotinamide, a form of vitamin B3, significantly lowers the risk of common, non-melanoma skin cancer in high-risk patients, researchers reported on Oct. 21,… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
